A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice

BACKGROUND: Alzheimer’s disease (AD) is the most common form of dementia, the number of affected individuals is rising, with significant impacts for healthcare systems. Current symptomatic treatments delay, but do not halt, disease progression. Genetic evidence points to aggregation and deposition o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Neurodegener
Main Authors: Neumann, Ulf, Rueeger, Heinrich, Machauer, Rainer, Veenstra, Siem Jacob, Lueoend, Rainer M., Tintelnot-Blomley, Marina, Laue, Grit, Beltz, Karen, Vogg, Barbara, Schmid, Peter, Frieauff, Wilfried, Shimshek, Derya R., Staufenbiel, Matthias, Jacobson, Laura H.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4559881/
https://ncbi.nlm.nih.gov/pubmed/26336937
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13024-015-0033-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados